You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
McKesson
Boehringer Ingelheim
Harvard Business School

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,217,033

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,217,033 protect, and when does it expire?

Patent 8,217,033 protects NAYZILAM and is included in one NDA.

Summary for Patent: 8,217,033
Title:Methods and compositions for the delivery of a therapeutic agent
Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Inventor(s): Gizurarson; Sveinbjorn (Reykjavik, IS)
Assignee: Hananja EHF (Reyjavik, IS) University of Iceland (Reykjavik, IS)
Application Number:12/469,448
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,217,033

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc NAYZILAM midazolam SPRAY;NASAL 211321-001 May 17, 2019 RX Yes Yes   Start Trial   Start Trial Y ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,217,033

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Iceland8593/2007Jan 19, 2007

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKesson
Moodys
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.